Chunghwa Chemical Synthesis & Biotech Co Ltd

Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) is a prominent Contract Manufacturing Organisation (CMO) and Contract Development and Manufacturing Organisation (CDMO) within the pharmaceutical industry. Established in 1964, CCSB operates one of the largest Active Pharmaceutical Ingredient (API) manufacturing facilities in Taiwan. It is an FDA and EU approved cGMP API plant, dedicated to producing both synthesis and biotechnology products. The company has successfully filed for US DMF, EDMF, and COS for numerous products, which include Mycophenolate Mofetil, Rapamycin (Sirolimus), Tacrolimus Monohydrate, Everolimus, and Caspofungin Acetate. In addition to API production, CCSB provides contract manufacturing services from its cGMP plants and is currently engaged in supplying APIs and intermediates to clients, particularly in the European market.

Services include:
- Regulatory Services
- Containment
- APIs (Active Pharmaceutical Ingredients)
- Protein and Peptide
- Analytical Services
- Contract Development and Manufacturing (CDMO)

Chunghwa Chemical Synthesis & Biotech Co Ltd continues to be a pivotal supplier in the pharmaceutical industry, offering a wide array of services to meet the evolving needs of its clients. For further information, please visit ccsb.com.tw.